Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
Pp 2187 - 2195

Metabolomics in Laboratory Medicine Unveiling Disease Pathophysiology: Review

[1]- Turki Mhammad Zarea Qranbaish,[2]-Naif Nahedh Rashad Al Harbi,[3]- Wafa Ibrahim Dhaifallah Qumayri,[4]-Adeeb Abdullatif Saleh Alshuwaier,[5]-Fatmah Naser Mohsin Mashary,[6]-Basma Abdall Ali Afif,[7]-Fatimah Madani Hadi Abutaleb,[8]-Fatimah Mohammed Hussain Sherwani,[9]-Somaiah Ali Alharbi,[10]-Tahara Majali Ali Altherwi,[11]-Ibrahim Ahmed Q Alkhalifah,[12]-Ebtisam Abed Mohd Manaa,[13]-Ameen Ibrahim Ahmed Otaif,[14]- Fuad Hamad Mohammed Aeshi,[15]-Aimn Mohamed

1. Ksa, Ministry Of Health
2. Ksa, Ministry Of Health, King Salman Hospital
3. Ksa, Ministry Of Health, Center For Poison Control And Forensic Chemistry Jazan
4. Ksa, Ministry Of Health, King Salman Center For Kidney Diseases
5. Ksa, Ministry Of Health
6. Ksa, Ministry Of Health
7. Ksa, Ministry Of Health, Sabya Hospital
8. Ksa, Ministry Of Health, Say Hospital
9. Ksa, Ministry Of Health, Jazan General Hospital
10. Ksa, Ministry Of Health, Maternity And Children's Hospital In Buraydah
11. Ksa, Ministry Of Health, Alomran General Hospital _Alahsa
12. Ksa, Ministry Of Health, Sabya Hospital
13. Ksa, Ministry Of Health, Moataq Al-Assam Primary Health Care Center
14. Ksa, Ministry Of Health, Alaredah General Hospital
15. Ksa, Ministry Of Health, Alaradh Primary Health Care Center

Abstract

Background: Metabolomics, as a key component of the omics revolution, offers insights into biochemical processes by profiling metabolites that reflect an organism's physiological state. This review explores the role of metabolomics in laboratory medicine, particularly its applications in disease pathophysiology.

Methods: This study synthesizes findings from various research articles and reviews on metabolomics, focusing on its methodologies, such as nuclear magnetic resonance (NMR) and mass spectrometry (MS), which enable the analysis of metabolites in biological samples. We examined the integration of metabolomics with other omics technologies to enhance our understanding of complex diseases, including obesity, diabetes, and cancer.

Results: Our analysis highlights that metabolomics can identify unique metabolic signatures associated with specific diseases, thereby aiding in diagnosis, prognosis, and personalized therapy. For instance, biomarkers linked to type 2 diabetes and cardiovascular diseases have been established, providing valuable insights for clinical applications. Furthermore, the integration of metabolomic data with genomic and proteomic data has revealed novel therapeutic targets and pathways.

Conclusion: Metabolomics has emerged as a powerful tool in laboratory medicine, advancing our understanding of disease mechanisms and facilitating the development of targeted therapies. Future research should focus on standardizing methodologies and integrating metabolomics with other omics disciplines to fully leverage its potential in clinical settings.

Keywords: Metabolomics, disease biomarkers, laboratory medicine, personalized therapy, omics integration.

Received: 13 october 2023 **Revised:** 27 November 2023 **Accepted:** 11 December 2023

1. Introduction

Technological advancements have dramatically expedited medical breakthroughs. The omics revolution has provided substantial help in biomedical research. Metabolic information may be monitored across many omics' levels, including genomes, transcriptomics, proteomics, and metabolomics, organized to categorize biochemical processes as shown by the basic dogma of molecular biology [1]. These omic methods delineate the biochemical arrangement of the human body. Genomics and transcriptomics have been thoroughly examined, mostly concentrating on nucleic acids [2,3]. For several decades, proteomics research has coincided with that of genomes. The initiation of the Human Genome Project has advanced genomic technology, yet a thorough and current examination of the proteome continues to pose financial and technological challenges. Metabolites and proteins may delineate an individual's metabolic state by mirroring the genomic encoding and environmental modifications at a particular moment [4,5]. This review emphasizes the metabolome, which serves as the most accurate and dynamic assessment of a phenotype at the molecular level. The metabolome represents the last phase of metabolism at a particular moment in time. It is well recognized as a leader in biological discoveries, aiming to identify easily measurable biomarkers and elucidate processes of pathophysiological significance.

The intricate metabolome comprises hundreds of interconnected metabolic events, including both tiny and big molecules. Metabolomics has developed as a technical instrument for quantifying and evaluating a diverse array of chemicals, including amino acids, carbohydrates, and lipids, derived from biological matrices, fluids, tissues, and other cellular fractions [7,8]. Canadian scientists delineated and documented the first edition of the metabolome, including 2500 metabolites, 1200 pharmaceuticals, and 3500 dietary constituents [9,10]. This was one of the first endeavors to delineate the human metabolome on an extensive scale.

2. The Promise of Metabolomics in Biomedical Applications

The analysis of the metabolome yields, and will continue to yield, a compilation of unique metabolites and the synthesis of their profiles for medicinal applications. This will notify professionals, at certain intervals, about a disease's inception, progression, or amelioration. This practice will improve diagnosis, prognosis, monitoring, and individualized pharmacotherapy. Moreover, metabolomic research may facilitate the identification of biomarkers for both prevalent and uncommon disorders [11]. The following sections delineate several uses of metabolomics in intricate disorders, including obesity, diabetes, and cancer. Current clinical uses for uncommon illnesses include newborn screening capable of diagnosing over 50 hereditary metabolic abnormalities, such as aminoacidopathies, organic acidemias, fatty acid oxidation disorders, and lysosomal storage disorders [12].

An effective strategy in the domain of inborn errors of metabolism involves the identification of pathogenic variants and its implementation with a comprehensive examination of untargeted metabolomics and whole-exome or whole-genome sequencing. This technique will enhance gene–metabolite annotations [13,14]. The cell metabolome is characterized by a profile of metabolites that indicate cellular physiology at a certain moment, which may or may not correspond to a pathological condition [15,16]. The compilation of interacting metabolites may indicate compounds that function as modulators of biological processes and phenotypes, potentially leading to the identification of novel pharmacological targets or therapeutic and nutritional treatments [17].

Ortmayr et al. [18] developed a global network model including three levels of biological information: the transcriptome, the proteome, and the metabolome. They investigated the inherent phenotypic variety using an in vitro cell line system by including intracellular metabolic profiles of 54 cancer cell lines derived from various tissue types or circumstances. They examined the reciprocal flow of signaling information between transcription regulators and metabolic pathways via this technique. Transcription regulator refers to any entity that modulates gene expression, including transcription factors, chromatin remodelers, and co-regulators [19]. Endogenous metabolites capable of modulating transcription regulator activity may serve as useful chemical scaffolding for developing novel therapeutic agents targeting oncogenic regulators. The researchers identified novel regulatory linkages between several transcription regulators and essential metabolic pathways, indicating a broad array of transcriptional strategies that cells might use to meet anabolic and catabolic demands for rapid proliferation and adaptability to nutritional limitations. The metabolites influencing transcription regulator function are notably abundant with essential signaling chemicals that allosterically modulate several enzyme activities, including glutathione, glutamate, and ATP. They detected a worldwide correlation between glucose and one-carbon metabolism, indicating a selective sensitivity to antifolate medicines in cell lines with diminished glucose uptake. This metabolic reaction may serve as a diagnostic flag for cancer cells that are more prone to react to folate-production inhibitors [18].

Metabolites possess diverse biochemical roles, therefore increasing the impetus to accurately characterize the whole human metabolome and expedite the creation of a complete repository of therapeutically relevant and beneficial metabolite profiles. This will facilitate research into detailed functions and physiological roles in health and illness, particularly concerning the involvement of genes and metabolic pathways relevant to medication treatment or food, such as pharmacogenomics and nutrition, in aging and acute or chronic disorders. Enhancing metabolomics research might be achieved by the integration and standardization of several technologies. Efforts are underway to comprehensively characterize a given phenotype throughout time by using analytical and statistical methods to discover metabolites and metabolic pathways linked to certain illnesses and their development and progression [5].

A primary problem in metabolomics research is the presence of many metabolites exhibiting considerable chemical complexity, including diverse functional groups, varying physical and chemical characteristics, a broad spectrum of lipophilicity and pKa, carbon chain length, and chirality, among other factors. The lipidome constitutes two-thirds of the plasma metabolome and comprises several thousand lipids from at least 15 distinct chemical groups. Furthermore, it remains ambiguous if a distinct metabolomic profile corresponds to the metabolism of a particular organ, tissue, nutritional consumption, microbiome activity, or the interaction between the microbiome and the environment [20].

This study seeks to illustrate the present function of human metabolomics and its use in biomedical research, including its potential to address chronic illnesses like cancer and diabetes and its capacity to enhance aging and pharmacogenomics. Furthermore, we investigate the impact of metabolomics research on molecular biology, including the metabolome of the exposome and extracellular vesicles, as well as its potential for diagnostic and therapeutic applications. Given that the investigation of the human metabolome requires many analytical platforms to address the majority of metabolites in a clinical sample, we have included a review of various analytical methodologies pertinent to this work [21].

3. Fundamental Approaches in Metabolomics

A comprehensive elucidation of the analytical methodologies used to identify both small and big metabolites exceeds the parameters of this study. Nonetheless, we provide a comprehensive overview of the principal strategies, and some complexities associated with them. A diverse array of matrices may be examined from various tissues and bodily fluids, including plasma, serum, cerebrospinal fluid (CSF), pus, saliva, feces, cervicovaginal secretions, and urine [22-29]. However, several additional varieties of biofluids have been used in clinical settings. These include sputum, bronchial washings, saliva, perspiration, tears, cerebrospinal fluid, pleural or ascitic effusions, fecal water, bile, breast milk, amniotic fluid, seminal plasma, expressed prostatic secretions, among others [30-35]. The Metabolomics Society has created recommendations for documenting information about biospecimen origin, collection, and processing [36].

Widely used in metabolomics, proven methodologies using nuclear magnetic resonance (NMR) and mass spectrometry (MS) may be integrated with gas or liquid chromatography, capillary electrophoresis, or ultra-performance liquid chromatography (UPLC) [37,38]. The analytical platform for determining the metabolites of interest will be dictated by their physical and chemical characteristics, as well as those of their matrices.

The identification of a metabolome as an extensive list of metabolites by precise spectrometry quantification is intricate owing to the chemical complexity of the metabolome, the dynamic range of metabolites, fluctuating quantities, and the difficulties associated with simultaneous quantification in complicated mixtures. This creates a substantial bottleneck in the sector, hindering the production of vital biomedical knowledge. Alseekh et al. [39] published comprehensive guidelines for mass spectrometry in metabolomic research, addressing sample preparation, replication randomization, quantification, recovery, recombination, ion suppression, and peak misidentification to facilitate high-quality reporting of liquid and gas chromatography (LC/GC) and mass spectrometry-derived metabolomic data.

Sphingolipid measurement requires previous LC/GC separation from other lipids. If double-bond information is essential, chiral columns are required, followed by mass spectrometry analysis, which may use a triple quadrupole for regular applications or time-of-flight spectrometry for method development or research, since it offers superior accuracy and mass resolution. Hydrophilic compounds and matrices, such as purine bases in urine, plasma, or cerebrospinal fluid, are effectively analyzed by NMR; however, if the objective is to identify lipids within these hydrophilic matrices, chromatographic separation is required, followed by mass spectrometry analysis and identification.

A crucial stage in metabolomics is selecting between focused and untargeted analysis [40]. The former aims to identify a predetermined array of metabolites and may be used to recognize and authenticate certain metabolites. The latter will identify hundreds or thousands of metabolites without a specified target list. All elements identified by the analytical platform may be subjected to further examination. This technique facilitates the assessment of alterations in the overall metabolic profile and the identification of previously unrecognized metabolites, therefore advancing biomedical research. This document aims to elucidate the prevailing developments in metabolomics and the requisite demands for the clinical implementation of its instruments. This version excludes chemical and analytical data, which are available in multiple important studies by Sanchez-Lopez, Losacco, and Theodoridis [41-43].

The identification of metabolomic signatures for health and illness will provide biological applications to enhance the effective distinction of pathophysiological conditions, diagnosis, tailored therapy, and medication development. Human metabolomics research aims to illustrate, in real-time, the tiny and big molecules that define health and disease conditions. The discovery of metabolomic signatures may facilitate prevention and enhance healthcare therapy. Metabolomics research involves a diverse array of analytical techniques and samples, primarily grounded on the physicochemical characteristics of biological matrices and the relevant metabolites. Metabolomics investigations may be categorized as focused or non-targeted, hypothesis-free or hypothesis-generating, aimed at identifying, defining, validating, and applying molecular signatures to advance medical advancement.

Current initiatives focus on amalgamating metabolomic data from many sources to provide a full phenotype of a particular health or illness condition. The sources include several analytical platforms, including NMR, gas chromatography, liquid chromatography, and mass spectrometry; diverse discovered metabolites, including lipids, amino acids, proteomics, glycomics, and others; various matrices, including blood, plasma, cerebrospinal fluid, urine, tissue, malignancies, etc. The metabolome fluctuates according to temporal variables, disease, developmental stages, progression, pharmacological therapy, dietary modifications, environmental influences, and the microbiome. The concurrent and precise analytical measurement of the metabolome is recognized as a difficulty [21].

The combined use of metabolomics and other omics technologies will address some problems and provide a more accurate identification and correlation of a full human phenotype. This also poses mathematical and statistical challenges, since a diverse range of data from several omic sources must be combined [44]. An instance of effective omics integration is shown in type 2 diabetes (T2D), where genomics and metabolomics, together with pathway analysis, have revealed branched-chain amino acid

(BCAA) levels as probable contributors to diabetes mellitus. Initially, metabolomics determined the amounts of branched-chain amino acids (BCAAs) linked to the enzymatic route of the alpha-keto acid dehydrogenase (BCKD) complex, which serves as the rate-limiting step in BCAA catabolism. The PPM1K gene, a mitochondrial phosphatase gene, was linked to the synthesis of branched-chain amino acids (BCAAs), establishing a connection among these three entities [45]. The presence of multi-omic data does not consistently permit straightforward inferences on illness or phenotypic causality. Integrated omics have provided several layers of data that corroborate and validate independent findings aimed at consolidating biological theories [46,47].

Advancements in analytical methods are necessary for metabolomics to completely develop as a clinical instrument. Classical metabolomics necessitates substantial sample sizes, ranging from milliliters to microliters, presenting a distinct challenge for specific biofluids [48]. Fortunately, innovative techniques, such as triboelectric nanogenerator inductive (TENGi) mass spectrometry, can operate within the sub-nanoliter volume range. It has been used in both targeted and non-targeted modes, proving effective in the analysis of exosomes, tissue-derived cells, needle biopsies, tears, and perspiration, all of which may be obtained in minimal quantities. TENGi MS coupling seems to enhance metabolite coverage and applies to almost all sample types with minimal quantities collected [49].

Alongside the advancement of superior analytical tools, there is a need for the worldwide standardization of metabolomic studies. Similar to previous instances in clinical trials, drug development, genomics, and pharmacogenomics, metabolomics now lacks established processes for the reporting and validation of results. Consequently, a cohesive agreement on the definition of a therapeutically relevant and meaningful metabolomic signature remains absent. Schmith et al. asserted the necessity for standardized protocols, cost-effective instruments, and accessible analytical platforms to facilitate the widespread application of metabolomics in research and its integration into clinical laboratories, addressing the growing demand for diagnostic and prognostic tests [21]. Furthermore, the algorithms used in route analysis need the standardization of methodologies, sample preparation, instrument specifications, and configurations, as well as quality standards. In this context, OmicsDI (www.omicsdi.org) may resolve some complexities. OmicsDI is an open-source platform that consolidates and archives a variety of omics data, accessible for download and research. This resource advocates for data-driven research, hence reducing repetition in trials. Future initiatives must address computational and statistical obstacles to standardize metabolomic analysis and reporting, therefore leveraging the potential of integrated metabolomics and systems biology [50].

Ultimately, integrated omics studies seek to develop genome-scale metabolic models that include phenotypic data for each illness or health condition. Systems biology can already generate maps of metabolic networks inside physiological systems. Integrating it with empirical metabolomic data would not only corroborate prior findings but also reinforce existing ideas and hypotheses, enhancing the comprehension of tissues, organs, or whole organisms about human health and illness [51].

The predominant health issues now are chronic illnesses and those associated with an aging population. These include Type 2 Diabetes, along with cardiovascular and neurological disorders. Metabolomics has the potential to enhance the treatment of various illnesses, augment lifespan, and provide personalized pharmacotherapy. Currently, many validated metabolomic signatures exist for type 2 diabetes and its sequelae, including renal illness as well as cardiovascular and neurological disorders. Metabolites, including VLDL, AC, BCAA, mono- and polyunsaturated fatty acids, and ether phospholipids, have been continuously identified over the last decade as significant metabolites associated with T2D, CVD, and neurodegeneration. These metabolites have been aggregated and verified as distinct metabolomic signatures. The subsequent phases include identifying methods to integrate metabolomic signatures into clinical practice and achieving a more favorable cost-benefit ratio to enhance diagnosis, prognosis, and therapy using metabolomics [52].

The intricate and delicate structure of the metabolome necessitates that investigations maintain consistency, minimizing variance across participants. They should also emphasize the dissemination of information and reports.

Metabolomics has identified distinct biomarkers for disease development and therapeutic effectiveness. For instance, ACs and aromatic amino acids are associated with insulin resistance, particular phosphocholines correlate with cardiovascular disease, an elevation of drug metabolites is linked to the likelihood of unfavorable drug responses, and long-chain sphingolipids and polyunsaturated fatty acids are related to female lifespan. Present efforts should emulate these findings and authenticate them to provide, in the future, a compilation of beneficial and therapeutically relevant metabolomic signatures to enhance human health.

4. Conclusions

Metabolomics significantly advances biomedical research by identifying indicators for diagnosis, illness monitoring, and treatment effectiveness, hence enhancing patient quality of life. Analytical approaches have significantly aided in identification and are sometimes used in clinical settings. The primary constraint of any metabolomic analysis platform is its inability to fully define the whole phenotype. Consequently, future metabolomic objectives will include the creation of more extensive analytical platforms and the amalgamation of metabolomic data from various devices. Future technical advancements may provide devices capable of analyzing all or the majority of metabolites, irrespective of their chemical composition, necessitating just a single equipment configuration. Ultimately, multi-omic methodologies will provide a more comprehensive molecular comprehension of human metabolomics in both health and illness. This is crucial for directing innovative diagnosis and treatments [215]. Innovative or integrated analytical methodologies, including metabolite imaging, statistical analyses, and computer algorithms, are critically needed for metabolomics to establish itself as a tool with analytical validity and therapeutic use.

References

1. Crick, F. Central dogma of molecular biology. Nature 1970, 227, 561–563.
2. Brem, R.B.; Kruglyak, L. The landscape of genetic complexity across 5700 gene expression traits in yeast. Proc. Natl. Acad. Sci. USA 2005, 102, 1572–1577.
3. Oresic, M.; McGlinchey, A.; Wheelock, C.E.; Hyotylainen, T. Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health. Metabolites 2020, 10, 454.
4. Neavin, D.; Kaddurah-Daouk, R.; Weinshilboum, R. Pharmacometabolomics informs pharmacogenomics. Metabolomics 2016, 12, 121.
5. Johnson, C.H.; Ivanisevic, J.; Siuzdak, G. Metabolomics: Beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 2016, 17, 451–459.
6. Nielsen, J. Systems Biology of Metabolism. Annu. Rev. Biochem. 2017, 86, 245–275.
7. Powers, R. NMR metabolomics and drug discovery. Magn. Reson. Chem. 2009, 47 (Suppl 1), S2–S11.
8. Zhang, G.F.; Sadhukhan, S.; Tochtrop, G.P.; Brunengraber, H. Metabolomics, pathway regulation, and pathway discovery. J. Biol. Chem. 2011, 286, 23631–23635.
9. Wishart, D.S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A.C.; Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; et al. HMDB: The Human Metabolome Database. Nucleic Acids Res. 2007, 35, D521–D526.
10. Harrigan, G.G.; Goodacre, R. Introduction. In Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis; Harrigan, G.G., Goodacre, R., Eds.; Springer: Boston, MA, USA, 2003; pp. 1–8.
11. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 2016, 15, 473–484.
12. Mussap, M.; Zaffanello, M.; Fanos, V. Metabolomics: A challenge for detecting and monitoring inborn errors of metabolism. Ann. Transl. Med. 2018, 6, 338.
13. Spratlin, J.L.; Serkova, N.J.; Eckhardt, S.G. Clinical applications of metabolomics in oncology: A review. Clin. Cancer Res. 2009, 15, 431–440.

14. Griffiths, W.J.; Koal, T.; Wang, Y.; Kohl, M.; Enot, D.P.; Deigner, H.P. Targeted metabolomics for biomarker discovery. Angew. Chem. Int. Ed. Engl. 2010, 49, 5426–5445.
15. Jacob, F.; Monod, J. Genetic regulatory mechanisms in the synthesis of proteins. J. Mol. Biol. 1961, 3, 318–356.
16. Yang, Q.; Vijayakumar, A.; Kahn, B.B. Metabolites as regulators of insulin sensitivity and metabolism. Nat. Rev. Mol. Cell Biol. 2018, 19, 654–672.
17. Rinschen, M.M.; Ivanisevic, J.; Giera, M.; Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 2019, 20, 353–367.
18. Ortmayr, K.; Dubuis, S.; Zampieri, M. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat. Commun. 2019, 10, 1841.
19. Han, H.; Shim, H.; Shin, D.; Shim, J.E.; Ko, Y.; Shin, J.; Kim, H.; Cho, A.; Kim, E.; Lee, T.; et al. TRRUST: A reference database of human transcriptional regulatory interactions. Sci. Rep. 2015, 5, 11432.
20. Shevchenko, A.; Simons, K. Lipidomics: Coming to grips with lipid diversity. Nat. Rev. Mol. Cell Biol. 2010, 11, 593–598.
21. Schmidt, D.R.; Patel, R.; Kirsch, D.G.; Lewis, C.A.; Vander Heiden, M.G.; Locasale, J.W. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J. Clin. 2021, 71, 333–358.
22. Beger, R.D.; Schnackenberg, L.K.; Holland, R.D.; Li, D.; Dragan, Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2006, 2, 125–134.
23. Bathe, O.F.; Shaykhutdinov, R.; Kopciuk, K.; Weljie, A.M.; McKay, A.; Sutherland, F.R.; Dixon, E.; Dunse, N.; Sotiropoulos, D.; Vogel, H.J. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol. Biomark. Prev. 2011, 20, 140–147.
24. Beckonert, O.; Coen, M.; Keun, H.C.; Wang, Y.; Ebbels, T.M.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 2010, 5, 1019–1032.
25. Bharti, S.K.; Jaiswal, V.; Ghoshal, U.; Ghoshal, U.C.; Baijal, S.S.; Roy, R.; Khetrapal, C.L. Metabolomic profiling of amoebic and pyogenic liver abscesses: An in vitro NMR study. Metabolomics 2012, 8, 540–555.
26. Ramadan, Z.; Jacobs, D.; Grigorov, M.; Kochhar, S. Metabolic profiling using principal component analysis, discriminant partial least squares, and genetic algorithms. Talanta 2006, 68, 1683–1691.
27. Monleon, D.; Morales, J.M.; Barrasa, A.; Lopez, J.A.; Vazquez, C.; Celda, B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009, 22, 342–348.
28. Auray-Blais, C.; Raiche, E.; Gagnon, R.; Berthiaume, M.; Pasquier, J.-C. Metabolomics and preterm birth: What biomarkers in cervicovaginal secretions are predictive of high-risk pregnant women? Int. J. Mass Spectrom. 2011, 307, 33–38.
29. Khamis, M.M.; Adamko, D.J.; El-Aneed, A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom. Rev. 2017, 36, 115–134.
30. Wishart, D.S.; Jewison, T.; Guo, A.C.; Wilson, M.; Knox, C.; Liu, Y.; Djoumbou, Y.; Mandal, R.; Aziat, F.; Dong, E.; et al. HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res. 2013, 41, D801–D807.
31. Chen, W.; Li, C.; Shi, Y.; Zhang, Y.; Jin, D.; Zhang, M.; Bo, M.; Li, G. A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier. Front. Pharmacol. 2021, 12, 722627.
32. Wang, K.; Gaitsch, H.; Poon, H.; Cox, N.J.; Rzhetsky, A. Classification of common human diseases derived from shared genetic and environmental determinants. Nat. Genet. 2017, 49, 1319–1325.
33. Delgado-Povedano, M.M.; Calderon-Santiago, M.; Luque de Castro, M.D.; Priego-Capote, F. Metabolomics analysis of human sweat collected after moderate exercise. Talanta 2018, 177, 47–65.
34. Gardner, A.; Carpenter, G.; So, P.W. Salivary Metabolomics: From Diagnostic Biomarker Discovery to Investigating Biological Function. Metabolites 2020, 10, 47.
35. Serkova, N.J.; Van Rheen, Z.; Tobias, M.; Pitzer, J.E.; Wilkinson, J.E.; Stringer, K.A. Utility of magnetic resonance imaging and nuclear magnetic resonance-based metabolomics for quantification of inflammatory lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L152–L161.

36. Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.H.; Beger, R.; Daykin, C.A.; Fan, T.W.; Fiehn, O.; Goodacre, R.; Griffin, J.L.; et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 2007, 3, 211–221.
37. Dettmer, K.; Aronov, P.A.; Hammock, B.D. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 2007, 26, 51–78.
38. Gebregiworgis, T.; Powers, R. Application of NMR metabolomics to search for human disease biomarkers. Comb. Chem. High Throughput Screen 2012, 15, 595–610.
39. Alseekh, S.; Aharoni, A.; Brotman, Y.; Contrepois, K.; D'Auria, J.; Ewald, J.; Ewald, J.C.; Fraser, P.D.; Giavalisco, P.; Hall, R.D.; et al. Mass spectrometry-based metabolomics: A guide for annotation, quantification and best reporting practices. Nat. Methods 2021, 18, 747–756.
40. Roberts, L.D.; Souza, A.L.; Gerszten, R.E.; Clish, C.B. Targeted metabolomics. Curr. Protoc. Mol. Biol. 2012, 98, 30.2.1–30.2.24.
41. Sanchez-Lopez, E.; Lomonaco, T.; Sugimoto, M.; Qiu, Y.; Campanella, B. Editorial: Metabolomics in the Study of Unconventional Biological Matrices. Front. Chem. 2021, 9, 736661.
42. Losacco, G.L.; Ismail, O.; Pezzatti, J.; Gonzalez-Ruiz, V.; Boccard, J.; Rudaz, S.; Veuthey, J.L.; Guillarme, D. Applicability of Supercritical fluid chromatography-Mass spectrometry to metabolomics. II-Assessment of a comprehensive library of metabolites and evaluation of biological matrices. J. Chromatogr. A 2020, 1620, 461021.
43. Theodoridis, G.A.; Gika, H.G.; Wilson, I.D. (Eds.) Metabolic Profiling; Humana Press: New York, NY, USA, 2018; p. 291
44. Krassowski, M.; Das, V.; Sahu, S.K.; Misra, B.B. State of the Field in Multi-Omics Research: From Computational Needs to Data Mining and Sharing. Front. Genet. 2020, 11, 610798.
45. Lotta, L.A.; Scott, R.A.; Sharp, S.J.; Burgess, S.; Luan, J.; Tillin, T.; Schmidt, A.F.; Imamura, F.; Stewart, I.D.; Perry, J.R.; et al. Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. PLoS Med. 2016, 13, e1002179.
46. Ritchie, M.D.; Holzinger, E.R.; Li, R.; Pendergrass, S.A.; Kim, D. Methods of integrating data to uncover genotype-phenotype interactions. Nat. Rev. Genet. 2015, 16, 85–97.
47. Kopczynski, D.; Coman, C.; Zahedi, R.P.; Lorenz, K.; Sickmann, A.; Ahrends, R. Multi-OMICS: A critical technical perspective on integrative lipidomics approaches. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2017, 1862, 808–811.
48. Li, Y.; Bouza, M.; Wu, C.; Guo, H.; Huang, D.; Doron, G.; Temenoff, J.S.; Stecenko, A.A.; Wang, Z.L.; Fernandez, F.M. Sub-nanoliter metabolomics via mass spectrometry to characterize volume-limited samples. Nat. Commun. 2020, 11, 5625.
49. Perez-Riverol, Y.; Bai, M.; da Veiga Leprevost, F.; Squizzato, S.; Park, Y.M.; Haug, K.; Carroll, A.J.; Spalding, D.; Paschall, J.; Wang, M.; et al. Discovering and linking public omics data sets using the Omics Discovery Index. Nat. Biotechnol. 2017, 35, 406–409.
50. Chan, S.Y.; White, K.; Loscalzo, J. Deciphering the molecular basis of human cardiovascular disease through network biology. Curr. Opin. Cardiol. 2012, 27, 202–209.
51. Cook, D.J.; Nielsen, J. Genome-scale metabolic models applied to human health and disease. Wiley Interdiscip. Rev. Syst. Biol. Med. 2017, 9, e1393.
52. Crowther, L.M.; Poms, M.; Plecko, B. Multiomics tools for the diagnosis and treatment of rare neurological disease. J. Inherit. Metab. Dis. 2018, 41, 425–434.

علم الميتابولوميات في الطب المخبري: كشف آليات أمراض الجسم - مراجعة

المستخلص

الخلفية :يُعد علم الميتابولوميات أحد المكونات الرئيسية في ثورة علم الـ"أومكس"، حيث يوفر رؤى حول العمليات البيوكيميائية من خلال تحليل الميتابوليتات التي تعكس الحالة الفسيولوجية للكائن الحي. تستعرض هذه المراجعة دور الميتابولوميات في الطب المخبري، وتركز على تطبيقاتها في فهم آليات الأمراض.

الطرق :تتناول هذه الدراسة مجموعة من المقالات البحثية والمراجعات المتعلقة بالميتابولوميات، مع التركيز على منهجياتها مثل الرنين المغناطيسي النووي (NMR) وقياس الطيف الكتلي(MS) ، التي تمكن من تحليل الميتابوليتات في العينات البيولوجية. كما تم بحث دمج الميتابولوميات مع تقنيات أومكس الأخرى لفهم الأمراض المعقدة مثل السمنة، والسكري، والسرطان

النتائج :أظهرت تحليلاتنا أن الميتابولوميات يمكنها تحديد توقيعات أيضية فريدة مرتبطة بأمراض معينة، مما يُسهم في التشخيص والتنبؤ والعلاج المخصص. على سبيل المثال، تم تحديد مؤشرات حيوية مرتبطة بمرض السكري من النوع الثاني وأمراض القلب والأوعية الدموية، مما يوفر رؤى قيمة للتطبيقات السريرية. علاوة على ذلك، كشف دمج بيانات الميتابولوميات مع بيانات الجينوميات والبروتيوميات عن أهداف علاجية ومسارات جديدة.

الاستنتاج :برزت الميتابولوميات كأداة قوية في الطب المخبري، حيث عززت فهمنا لآليات الأمراض وساهمت في تطوير علاجات موجهة. يجب أن تركز الأبحاث المستقبلية على توحيد المنهجيات ودمج الميتابولوميات مع تخصصات أومكس الأخرى للاستفادة الكاملة من إمكاناتها في الإعدادات السريرية.

كلمات المفتاحية :الميتابولوميات، المؤشرات الحيوية للأمراض، الطب المخبري، العلاج المخصص، تكامل تقنيات أومكس.